Modern hormone therapy did not raise cardiovascular risk in a large long-term cohort
Contemporary hormone replacement therapy was not associated with higher rates of heart attack, stroke, blood clots or premature death among women ages 45 to 59 in a large Israeli cohort followed for an average of 12 years. The finding comes from health records covering more than 52,000 women and adds a substantial real-world data set to a question that has shaped menopause care for decades.
For many women, the decision to start hormone therapy has been filtered through fear of cardiovascular harm. That hesitation has been reinforced by earlier randomized trials, yet much of that older evidence came from formulations and prescribing patterns that do not match current practice. The present analysis focused on modern oral, transdermal patch and gel formulations, the therapies now used most often when menopausal symptoms are severe enough to justify treatment.
The biological question is straightforward, even if the clinical answer has been hard to settle. Estrogen and progestogen exposure can influence vascular tone, coagulation pathways and lipid metabolism, so timing, dose and route of administration matter. A therapy started soon after menopause in a healthy woman is not the same exposure as a higher-dose regimen begun years later in a person with established vascular disease.
Event rates stayed nearly identical between hormone and non-hormone groups
Investigators compared women who started HRT with women of similar age, body mass index, blood pressure, cholesterol status, diabetes status, smoking history and socioeconomic profile who had recently seen a gynecologist but did not begin therapy. Both groups had no prior diagnosis of heart disease, blood clots or cancer.
Over follow-up, 2,311 women in the hormone therapy group, or 4.4%, experienced a heart attack, stroke or related heart disease, compared with 2,383 women, or 4.6%, in the non-HRT group. Death before age 80 occurred in 659 women taking hormone therapy, or 1.3%, versus 653 women, or 1.2%, among those not using hormones. Blood clots were uncommon and occurred at the same rate in both groups: 174 women in the HRT group and 175 in the comparison group, or 0.33% in each arm.
The numbers did not separate in a way that would suggest an excess cardiovascular penalty from contemporary hormone therapy in this age range. Even after long follow-up, the event curves remained closely aligned.
Route of administration did not change the safety signal
The findings were similar whether therapy was given orally, through a patch or as a gel. That consistency matters because route of delivery can alter hepatic first-pass effects, which in turn may influence clotting factors and inflammatory signaling. Transdermal dosing has often been viewed as a potentially gentler option for vascular biology, but the present data did not show a meaningful separation by formulation across the study population.
The cohort design also strengthens the relevance of the findings to everyday practice. These were not highly selected trial volunteers living under rigid protocols. They were women in routine care, many of them likely making real-world choices about symptom relief, sleep disruption, hot flashes and quality of life while trying to weigh long-term risk against immediate benefit.
Why timing around menopause remains central to interpretation
Current clinical guidance recommends starting hormone therapy within 10 years of menopause onset and before age 60. That recommendation fits the broader idea that vascular risk is not static across the menopausal transition. Endothelial function, metabolic status and atherosclerotic burden all change with age and with years since estrogen decline.
The present study aligns with that timing framework. It focused on women 45 to 59, a group in whom therapy is more often considered for symptom control near the menopausal transition rather than as a late reinitiation after years of untreated menopause. In that context, the absence of an observed increase in cardiovascular events supports the growing view that age at initiation and baseline vascular health shape the risk profile as much as the drug itself.
Stacey E. Rosen, a women’s heart health specialist who was not involved in the research, said the data add to evidence that today’s hormone therapy options may not increase the risk of heart disease, stroke or blood clots for healthy women who begin treatment around menopause. The practical implication is not that every woman should take hormone therapy, but that cardiovascular fear alone should not automatically exclude it from discussion.
Observational data support reassurance, not certainty
This was an observational study, so it cannot prove causation. Residual differences between women who chose hormone therapy and those who did not may still have influenced outcomes. Exercise habits, diet, unrecorded medical problems and the severity of menopausal symptoms were not fully captured in the records.
The analysis also grouped women by the first hormone therapy they used and did not track changes in formulation over time. A woman who switched from one preparation to another during the follow-up period would still be counted in the original category, which can blur subtle effects of drug switching or escalation. Those constraints do not erase the signal, but they do limit how aggressively the findings can be generalized.
What the long follow-up adds to the menopause discussion
The study followed women for up to 23 years, with an average of 12 years, giving the analysis a long horizon unusual for many menopause studies. Long observation is particularly useful for cardiovascular outcomes, which often evolve slowly and can be influenced by years of exposure rather than short-term symptom treatment.
A more contemporary evidence base has already been moving in this direction. The FDA removed black box warnings from hormone therapy products in 2025 after reviewing current scientific data that did not show increased risk of cardiovascular disease, breast cancer or dementia. This new cohort does not settle every question, but it fits with the broader shift away from older, more alarming interpretations of hormone therapy risk.
For clinicians, the bedside question remains practical: which woman is healthy enough, symptomatic enough and close enough to menopause onset to consider therapy? This dataset says that in women 45 to 59 without prior cardiovascular disease, blood clots or cancer, modern hormone therapy did not show an excess of heart attack, stroke, venous thromboembolism or early death over long follow-up.
The study is still a preliminary abstract, so the final answer will depend on full peer-reviewed publication, including more detail on confounding, prescribing patterns and subgroup effects. Until then, the data offer a measured but meaningful reassurance: in appropriately selected women, contemporary hormone therapy did not carry an observed cardiovascular penalty in this large real-world cohort.